90098-04-7
90098-04-7 structure
- Name: Rebamipide
- Chemical Name: Rebamipide
- CAS Number: 90098-04-7
- Molecular Formula: C19H15ClN2O4
- Molecular Weight: 370.786
- Catalog: API Digestive system medication Acid and gastric mucosal protective drugs
- Create Date: 2018-02-12 08:00:00
- Modify Date: 2026-07-04 20:49:03
-
Rebamipide is an inducer of endogenous prostaglandin and a oxygen-derived free radical scavenger.Target: OthersRebamipide is the first anti-gastric ulcer and antigastritis drug that not only increases endogenous prostaglandin in gastric mucosa but also scavenges oxygen-derived free radicals and inhibits their production. The inhibitory effect of rebamipide on lipid peroxidation induced by a free radical initiator was also demonstrated by the in vitro system using rat gastric mucosal homogenates. These data indicate that rebamipide offers a potential for protection against reactive oxygen- and activated neutrophil-associated gastric mucosal injury by scavenging hydroxyl radical and inhibiting neutrophil activation or lipid peroxidation [1]. Rebamipide can contribute to the management of patients who are taking NSAIDs or are infected with H. pylori. Rebamipide may enhance eradication of H. pylori-infection using standard eradication therapy [2]. Rebamipide is beneficial for obtaining a better quality of ulcer healing and reduction of future ulcer relapse [3].
| Name | Rebamipide |
|---|---|
| Synonyms |
1H-benzimidazol-2-yl(4-chlorophenyl)methanone
2-(4-chlorobenzoylamino)-3-[2(1H)-quinolinone-4-yl]propionic acid REBAMIPIDE 2-(4-Chlorobenzamido)-3-(2-oxo-1,2-dihydro-4-quinolyl)propanoic Acid Proamipide 2-(4-Chlorobenzoylamino)-3-[2(1H)-quinolinon-4-yl]propionic acid 2-(4-Chlorobenzoylamino)-3-(1,2-dihydro-2-oxo-4-quinolyl)propionic acid Korea-FDA API 2-(4-CHLOROBENZAMIDO)-3-(2-OXO-1,2-DIHYDROQUINOLIN-4-YL)PROPANOIC ACID α-[(4-Chlorobenzoyl)amino]-1,2-dihydro-2-oxo-4-quinolinropanoic acid hydrate α-[(4-Chlorobenzoyl)amino]-1，2-dihydro-2-oxo-4-quinolinmpanoic acid N-(4-Chlorobenzoyl)-3-(2-hydroxyquinolin-4-yl)alanine OPC-12759, Mucosta, a-[(4-Chlorobenzoyl)-amino]-1,2-dihydro-2-oxo-4-quinolinropanoic Acid N-[(4-chlorophenyl)carbonyl]-3-(2-oxo-1,2-dihydroquinolin-4-yl)alanine Rebagen OPC-12759, Mucosta, α-[(4-Chlorobenzoyl)-amino]-1,2-dihydro-2-oxo-4-quinolinropanoic Acid hot selling Rebamipide 4-Quinolinropanoic acid, a-[(4-chlorobenzoyl)amino]-1,2-dihydro-2-oxo- (9CI) 2-[(4-chlorobenzoyl)amino]-3-(2-keto-1H-quinolin-4-yl)propionic acid Rebamipide hydrate Proamipide hydrate opc-12759 4-Quinolinropanoic acid, 1,2-dihydro-alpha-((4-chlorobenzoyl)amino)-2-oxo-, (+-) NSC1538 Rebamipide impurities Rebamupide OPC 12759 hydrate REACTIVE ORANGE 122,CINO.ORANGE 122 (111-6) rebamipide 2-(4-Dhlorobenzamido)-3-(2-oxo-1,2-dihydroquinolin-4-yl)propanoic acid (+-)-1,2-dihydro-alpha-((4-chlorobenzoyl)amino)-2-oxo-4-quinolinropanoica Rebapaite N-(4-Chlorobenzoyl)-3-(2-oxo-1,2-dihydroquinolin-4-yl)alanine 0PC-12759 2-(4-chlorobenzoyl)benzimidazole α-[(4-Chlorobenzoyl)amino]-1,2-dihydro-2-oxo-4-quinolinropanoic acid 1,2-dihydro-alpha-((4-chlorobenzoyl)amino)-2-oxo-4-quinolinropanoicaci( 2-dihydro-alpha-((4-chlorobenzoyl)amino)-2-oxo- (+-)-4-quinolinropanoic acid Mucosta hydrate Rebamipid 2-(4-Chlorobenzoylamino)-3-(1,2-dihydro-2-oxo-4 2-(4-Chlorobenzamido)-3-[2(1H)-quinolinon-4-yl]propionic Acid 2-[(4-chlorophenyl)cbonylamino]-3-(2-oxo-1H-quinolin-4-yl)propanoic acid 2-(4-Chlorobenzoylamino)-3-(2-oxo-1,2-dihydroquinolin-4-yl)propionic acid N-(4-Chlorobenzoyl)-3-(2-oxo-1,2-dihydro-4-quinolinyl)alanine Rebamipide, 10 mM in DMSO Rebamipide (HPLC) (+-)-2-(4-chlorobenzoylamino)-3-(2(1h)-quinolinon-4-yl)propionicacid Rui pat Rebamipide > 2-[(4-chlorobenzoyl)amino]-3-(2-oxo-1H-quinolin-4-yl)propanoic acid 2-(4-chlorobenzoylamino)-3-[2(1H)-quinolon-4-yl]propionic acid Rebamipide Inducer of endogenous prostaglandin and a oxygen-derived free radical scavenger 2-dihydro-alpha-((4-chlorobenzoyl)amino)-2-oxo-(+-)-4-quinolinropanoicaci Mucosta RebamipideRebamipide 2-(4-chlorobenzamido)-3-(2-oxo-1,2-dihydroquinolin-4-yl)propanoic acid RebamipideQ: What is Rebamipide Q: What is the CAS Number of Rebamipide Q: What is the storage condition of Rebamipide Ruibapaite Impurity 3 REBAMIPIDEREBAMIPIDE (R)-2-(4-chlorobenzamido)-3-(2-oxo-1,2-dihydroquinolin-4-yl)propanoic acid (+-)-1,2-Dihydro-alpha-((4-chlorobenzoyl)amino)-2-oxo-4-quinolinropanoic acid opc12759 REBAPIMIDE (±)-a-(p-Chlorobenzamido)-1,2-dihydro-2-oxo-4-quinolinepropionic acid MFCD00866895 Rebamipide reference standd 4-Quinolinropanoic acid, α-[(4-chlorobenzoyl)amino]-1,2-dihydro-2-oxo a-[(4-Chlorobenzoyl)amino]-1,2-dihydro-2-oxo-4-quinolinepropanoic acid NSC-1538 Proamipide|||OPC12759 |
| Description | Rebamipide is an inducer of endogenous prostaglandin and a oxygen-derived free radical scavenger.Target: OthersRebamipide is the first anti-gastric ulcer and antigastritis drug that not only increases endogenous prostaglandin in gastric mucosa but also scavenges oxygen-derived free radicals and inhibits their production. The inhibitory effect of rebamipide on lipid peroxidation induced by a free radical initiator was also demonstrated by the in vitro system using rat gastric mucosal homogenates. These data indicate that rebamipide offers a potential for protection against reactive oxygen- and activated neutrophil-associated gastric mucosal injury by scavenging hydroxyl radical and inhibiting neutrophil activation or lipid peroxidation [1]. Rebamipide can contribute to the management of patients who are taking NSAIDs or are infected with H. pylori. Rebamipide may enhance eradication of H. pylori-infection using standard eradication therapy [2]. Rebamipide is beneficial for obtaining a better quality of ulcer healing and reduction of future ulcer relapse [3]. |
|---|---|
| Related Catalog | |
| References |
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Boiling Point | 695.0±55.0 °C at 760 mmHg |
| Melting Point | 288-290ºC dec. |
| Molecular Formula | C19H15ClN2O4 |
| Molecular Weight | 370.786 |
| Flash Point | 374.1±31.5 °C |
| Exact Mass | 370.072021 |
| PSA | 99.26000 |
| LogP | 2.90 |
| Vapour Pressure | 0.0±2.3 mmHg at 25°C |
| Index of Refraction | 1.634 |
| Storage condition | -20°C Freezer |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
| HS Code | 2933790090 |
|---|
|
~96%
90098-04-7 |
| Literature: OTSUKA PHARMACEUTICAL CO., LTD. Patent: WO2006/59781 A1, 2006 ; Location in patent: Page/Page column 11-12 ; |
|
~94%
90098-04-7 |
| Literature: Lee, Byoung-suk; Chun, Myung-Hee Patent: US2003/87930 A1, 2003 ; |
|
~50%
90098-04-7 |
| Literature: Uchida; Tabusa; Komatsu; Morita; Kanbe; Nakagawa Chemical and Pharmaceutical Bulletin, 1985 , vol. 33, # 9 p. 3775 - 3786 |
|
~%
90098-04-7 |
| Literature: Chemical and Pharmaceutical Bulletin, , vol. 33, # 9 p. 3775 - 3786 |
|
~%
90098-04-7 |
| Literature: Chemical and Pharmaceutical Bulletin, , vol. 33, # 9 p. 3775 - 3786 |
| HS Code | 2933499090 |
|---|---|
| Summary | 2933499090. other compounds containing in the structure a quinoline or isoquinoline ring-system (whether or not hydrogenated), not further fused. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |